News

ASCO 2015: Dr. Maurie Markman gives his top picks in gynecologic research


 

References

Dr. Maurie Markman picks the upcoming ASCO presentations he anticipates to be the most interesting in gynecologic research.

Dr. Maurie Markman

Dr. Maurie Markman

5510 Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

5505 Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).

5506 An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.

5508 Results of ARIEL2: A phase II trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

5503 Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.

5502 Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial.

Dr. Maurie Markman is president, medicine and science, Cancer Treatment Centers of America.

Recommended Reading

Circulating tumor cells prognostic in advanced cervical cancer
MDedge Hematology and Oncology
Contamination prompts voluntary injectables recall
MDedge Hematology and Oncology
New light shed on olaparib therapy in ovarian cancer
MDedge Hematology and Oncology
AACR: Targeted combo active in triple-negative breast cancer, ovarian cancer
MDedge Hematology and Oncology
PAS: Texting beats phone reminders for HPV vaccine completion
MDedge Hematology and Oncology
ACOG: Practice and referral patterns may affect occult uterine sarcoma risk post hysterectomy
MDedge Hematology and Oncology
AACR: HPV vaccine may protect some women with prior exposure
MDedge Hematology and Oncology
Managing open wounds in ob.gyn.
MDedge Hematology and Oncology
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge Hematology and Oncology
Epithelial Ovarian Cancer: Management of Advanced Disease
MDedge Hematology and Oncology